NOVO B — Novo Nordisk A/S Balance Sheet
0.000.00%
- DKK1.52tn
- DKK1.60tn
- DKK290.40bn
- 93
- 37
- 15
- 44
Annual balance sheet for Novo Nordisk A/S, fiscal year end - December 31st, DKK millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 12,104 | 16,362 | 23,116 | 29,373 | 25,441 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 32,184 | 46,799 | 57,505 | 75,261 | 87,414 |
| Total Inventory | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 65,809 | 85,595 | 108,194 | 139,646 | 160,897 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 50,269 | 55,362 | 66,671 | 90,961 | 162,488 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 144,922 | 194,508 | 241,257 | 314,486 | 465,795 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 70,273 | 99,516 | 120,940 | 169,655 | 217,528 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 81,597 | 123,762 | 157,771 | 207,925 | 322,309 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 63,325 | 70,746 | 83,486 | 106,561 | 143,486 |
| Total Liabilities & Shareholders' Equity | 144,922 | 194,508 | 241,257 | 314,486 | 465,795 |
| Total Common Shares Outstanding |